Transition probabilities of HER2-positive and HER2-negative breast cancer patients treated with Trastuzumab obtained from a clinical cancer registry dataset.

Data Brief 2016 Jun 12;7:654-7. Epub 2016 Mar 12.

GECKO Institute for Medicine, Informatics and Economics, Heilbronn University, Max-Planck-Str. 39, 74081 Heilbronn, Germany.

Records of female breast cancer patients were selected from a clinical cancer registry and separated into three cohorts according to HER2-status (human epidermal growth factor receptor 2) and treatment with or without Trastuzumab (a humanized monoclonal antibody). Propensity score matching was used to balance the cohorts. Afterwards, documented information about disease events (recurrence of cancer, metastases, remission of local/regional recurrences, remission of metastases and death) found in the dataset was leveraged to calculate the annual transition probabilities for every cohort.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.dib.2016.03.039DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4802671PMC
June 2016
13 Reads

Publication Analysis

Top Keywords

breast cancer
8
clinical cancer
8
cancer patients
8
transition probabilities
8
cancer registry
8
cancer
5
factor receptor
4
recurrences remission
4
trastuzumab humanized
4
remission metastases
4
treatment trastuzumab
4
receptor treatment
4
epidermal growth
4
her2-status human
4
cohorts her2-status
4
dataset leveraged
4
death dataset
4
human epidermal
4
local/regional recurrences
4
metastases death
4

Similar Publications